Medico-economic and Quality of Life Impact of Sjogren-associated Small Fiber Neuropathy (SFINESS-QoLEco)
The Medico-economic Impact and Quality of Life of the Small-fiber Neuropathy Associated by Using Validated Scales (SF36, DN4, PROFAD SSI, ESPRI)
Sponsor: Assistance Publique - Hôpitaux de Paris
This observational or N/A phase trial investigates Medico-economic Impact and Primary Sjögren Syndrome and is currently actively recruiting participants. Assistance Publique - Hôpitaux de Paris leads this study, which shows 12 recorded versions since 2019 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
12 versions recorded-
Feb 2026 — Present [monthly]
Recruiting
-
Sep 2024 — Feb 2026 [monthly]
Recruiting
-
Aug 2024 — Sep 2024 [monthly]
Recruiting
Status: Unknown → Recruiting
-
Jul 2024 — Aug 2024 [monthly]
Unknown
Status: Unknown Status → Unknown
-
Aug 2023 — Jul 2024 [monthly]
Unknown Status
Status: Recruiting → Unknown Status
▶ Show 7 earlier versions
-
Sep 2021 — Aug 2023 [monthly]
Recruiting
-
Jan 2021 — Sep 2021 [monthly]
Recruiting
-
Sep 2020 — Jan 2021 [monthly]
Recruiting
-
Feb 2020 — Sep 2020 [monthly]
Recruiting
-
Feb 2019 — Feb 2020 [monthly]
Recruiting
Status: Not Yet Recruiting → Recruiting
-
Jun 2018 — Feb 2019 [monthly]
Not Yet Recruiting
-
May 2018 — Jun 2018 [monthly]
Not Yet Recruiting
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Assistance Publique - Hôpitaux de Paris
- LFB BIOMEDICAMENTS
For direct contact, visit the study record on ClinicalTrials.gov .